A comparative study of the effects of dimebon, obsidan, finoptin, and cordaron on the functional state of ischemic focus and size of necrotic zone in experimental myocardial infarction

Galenko-Yaróshevskii, P. A.; Melkumova, Emiliya; Bartashevich, V. V.; Uvarov, A. V.; Turovaya, A. Yu.; Khankoeva, A. I.; Galygo, D. S.

doi:10.1007/bf02445194

Cited by 1 publication

(2 citation statements)

References 4 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the results of these studies, Dimebon was classified as a low toxic substance. A pronounced antiarrhythmic effect of Dimebon and its beneficial effect in certain heart conditions have also been emphasized 21–23…”

Section: Discussionmentioning

confidence: 99%

“…A pronounced antiarrhythmic effect of Dimebon and its beneficial effect in certain heart conditions have also been emphasized. [21][22][23] In summary, Dimebon has a combination of pharmacological and safety properties that suggest the drug as a candidate for the use in the therapy of Alzheimer's disease. The results of the study reported here show that Dimebon has a great potential as a new medication that may not only improve cognitive functions, but, most importantly, may prevent the progression of the disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Antihistamine Agent Dimebon As a Novel Neuroprotector and a Cognition Enhancer

Bachurin

Bukatina

Lermontova

et al. 2001

Annals of the New York Academy of Sciences

206

149

View full text Add to dashboard Cite

Dimebon, launched earlier in Russia as an antihistamine drug, was evaluated as a representative of a new generation of anti‐Alzheimer's drugs that have two beneficial actions: (1) to alleviate symptoms, and (2) to prevent progression of the disease. The drug demonstrated cognition and memory‐enhancing properties in the active avoidance test in rats treated with the neurotoxin AF64A, which selectively destroys cholinergic neurons. Dimebon protected neurons in the cerebellum cell culture against the neurotoxic action of β‐amyloid fragment (Aβ25−35, EC50= 25 μM). In vitro, Dimebon displayed Ca2+‐blocking properties (IC50= 57 μM, on isolated rat ileum intestine) and pronounced anticholinesterase activity (IC50= 7.9 μM and 42 μM for butyrylcholine esterase and acetylcholine esterase, respectively). It also exhibited strong anti‐NMDA activity in the prevention of NMDA‐induced seizures in mice (EC50= 42 ± 6 mg/kg i.p.). A beneficial effect of Dimebon in the therapy of Alzheimer's disease was demonstrated in a pilot clinical trial performed in the Moscow Center of Gerontology. Fourteen patients who participated in the trial were evaluated for their state of personality and for the severity of the disease. The evaluation included orientation (space, place, time, and patient personality), memory for the past and present, life in present, speech, irritability, and so forth. During and after the eight‐week therapy with Dimebon, cognitive and self‐service functions of patients improved significantly, and psychopathic symptoms, anxiety, depression, tearfulness, and headache were substantially diminished. The results of these studies suggest Dimebon as a new candidate for the therapy of Alzheimer's‐like disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%